In response to ‘Mad About Science’
By Jim McCabe
Reader Contributor
I cringed at Brenden Bobby’s “Mad about Science” column on Ozempic in the Dec. 18 edition of the Reader. While it contained some factual information, it missed critical marks about what this new class of drugs really represents and read as alarmist rather than balanced health journalism.
The article raises legitimate concerns: Hollywood vanity culture, prohibitive costs and side effects that deserve serious consideration. These are valid points worth discussing.
But let’s address what it got wrong — and what it dangerously omitted.
The Gila monster myth and ‘vanity’ problem
The claim that semaglutide “mimics a compound from Gila monster venom” is doubly misleading. Having learned about these lizards, I find this framing absurd. Unlike rattlesnakes, Gila monsters don’t inject venom — they chew while venom flows along grooved teeth through capillary action, a primitive defensive mechanism.
More importantly, semaglutide isn’t “lizard venom.” Researchers studied exendin-4 from that venom to understand GLP-1 function, but semaglutide is a synthetic analog of human GLP-1 hormone — our own biochemistry, created in a lab. The framing makes it sound like patients are injecting reptile derivatives. They’re not.
Meanwhile, dismissing weight loss as “vanity” reveals misunderstanding of obesity as a chronic disease affecting over 40% of American adults. This brings life-threatening complications: heart disease, stroke, Type 2 diabetes, certain cancers, sleep apnea and osteoarthritis.
Obesity isn’t simple willpower. Genetics, hormones, metabolism, food environment and underlying conditions all play roles. Some people face genuine difficulty losing weight despite best efforts, often while battling serious health challenges obesity creates.
Responsible prescription should include exercise and lifestyle modifications. But here’s the inconvenient truth: exercise alone isn’t the silver bullet we’ve been told. The modern diet — heavily processed, calorie-dense, nutritionally poor — has created a food environment our bodies weren’t designed to handle. You can’t exercise your way out of systemic metabolic dysfunction any more than a diabetic can jog away insulin resistance.
What the article didn’t tell you
The column completely ignores breakthrough findings extending far beyond weight loss, including:
• Cardiovascular benefits — Clinical trials show significant reductions in heart attack and stroke risk—benefits persisting even after accounting for weight loss;
• Anti-inflammatory effects — Research demonstrates reduced inflammatory markers through mechanisms independent of metabolic changes, explaining benefits in liver disease, kidney disease, and potentially Alzheimer’s and Parkinson’s;
• Addiction research — Emerging studies show promise for alcohol and substance use disorders, with early trials showing 40% reductions in cravings and representing a potential breakthrough for conditions with limited treatment options.
The article also frames semaglutide as a “lifelong commitment” with absolute certainty, but reality is more nuanced. For some, these medications serve as stepping stones to healthier weight where maintenance becomes achievable. Others need ongoing treatment, often at smaller maintenance doses costing significantly less. The $1,000-per-month figure doesn’t account for this.
The landscape is evolving rapidly. Legitimate compounded versions run $200-$400/month — there’s a critical difference between accredited compounding pharmacies and “seedy circles on the internet.” Oral formulations are in development, and increased competition will drive costs down.
Then there’s the thyroid cancer scare. The warning about thyroid tumors comes from rodent studies lacking important context. Lab rats developed tumors at doses far exceeding human levels — and rodents have different thyroid biology. Current human data hasn’t shown this risk materializing. Should we monitor? Absolutely. Present as imminent danger? Irresponsible.
Finally, the article blames wealthy people for shortages without discussing manufacturing capacity, regulatory constraints or pandemic disruptions. Shortages happen for complex reasons. Framing it as rich people stealing from diabetics oversimplifies reality and stigmatizes people seeking treatment for legitimate chronic disease. In our community, anyone who could significantly benefit from GLP-1s might be deterred from exploring the option.
A balanced view
GLP-1 agonists represent genuine breakthroughs in treating obesity and metabolic disease. Like any medication, they come with risks, costs and limitations. They’re not magic, not right for everyone and shouldn’t replace lifestyle changes where possible.
But for many struggling with obesity — people who’ve tried everything, whose health is deteriorating — these medications offer hope where little existed before. Dismissing that as vanity or using alarmist framing does real harm.
We can have honest conversations about access, cost and appropriate use without stigma or scare tactics. Anyone considering these medications should consult their doctor and make informed decisions based on individual health. That’s responsible medicine. Not hysteria.
Jim McCabe is a local technology professional and all-around curious guy.
